A systematic review and meta-analysis in individuals with T2D by Ahmad et al. [101] (13 studies, n=1445) reported that SGLT-2 inhibitors + GLP-1 receptor agonists had shown favorable kidney outcomes (reduced urine albumin creatinine ratio and macroalbuminuria). Table 8 details the consensus recommendations. Here, GLP1R is linked to type 2 diabetes mellitus.